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| INTRODUCTION
Statin therapy has been well established as a cornerstone of cardiovascular prevention, and yet despite potent therapies for lowering low-density lipoprotein cholesterol (LDL-C), substantial residual risk remains. [1] [2] [3] Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events, and therefore may represent one contributive factor of residual CV risk beyond statin therapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] More recently, elegant Mendelian randomization studies have supported a causal role for TG in the pathogenesis of cardiovascular disease (CVD), showing that elevated TG are not merely a risk marker, but rather a risk factor and thus potentially modifiable. 3 Despite the available data, an important question that remains is whether treatment of modest degrees of TG elevation would decrease CV events, in particular in patients already receiving LDL-C-lowering therapy with statins. Prior CV outcome studies that administered therapies with TG-lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints. Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy, 6, [12] [13] [14] [15] and subgroup analyses suggested possible benefits to TG lowering in patients with dyslipidemia. 5, 6 Outcome studies of relatively low doses of prescription omega-3 therapies in Japan (the Japan EPA Lipid Intervention Study [JELIS]) 16 and Italy (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico [GISSI]) 17, 18 have suggested that omega-3 therapy may provide CV protection. However, these studies were performed in single countries prior to current treatment guidelines, and therefore provide supportive but not conclusive evidence of CV benefit.
Other more recent omega-3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient FIGURE 1 Study design for REDUCE-IT. During the screening period, patients were evaluated for inclusion/exclusion criteria. If patients met the inclusion criteria at Visit 1, they were asked to return for the randomization visit (Visit 2) and entered the treatment/follow-up period. Patients who were not eligible at Visit 1 but who became eligible in the next 28 days (such as patients whose statin dose changed at Visit 1 and/or needed to wash out prohibited medications) may have returned for an optional second screening visit (Visit 1.1). Such patients entered a statin stabilization/medication washout period of ≥28 days prior to rescreening. Patients who were eligible following screening/ rescreening entered the treatment/followup period, with follow-up visits occurring at 4 months, 12 months, and annually thereafter. *A study amendment (May 2013) was made, increasing the lower end of the fasting TG level from ≥150 mg/dL to ≥200 mg/dL to increase enrollment of patients with TG ≥200 mg/dL; it is anticipated that mean and median qualifying TG levels will be >200 mg/dL. †Final values to be known at study unblinding. Event-driven design: approximately 1612 primary efficacy events will be required during the study; study duration will vary accordingly. United States by the US Food and Drug Administration (FDA) as an adjunct to diet to reduce TG levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL). 25, 26 In this range of very elevated TG levels, reduction is considered to be clinically necessary to decrease the risk of pancreatitis.
In addition to beneficial changes to TG-rich lipoproteins and other plasma lipid markers, some clinical studies with higher-dose EPA also suggest beneficial effects on markers of oxidation and inflammation, coronary plaque characteristics, and major CV events. 16, 25, 26, 29, [31] [32] [33] For example, in contrast to the fenofibrate and niacin studies, JELIS found a 19% relative risk reduction in CV events in statin-treated patients with relatively normal TG but a more pronounced 53% reduction in the subgroup with mixed dyslipidemia, specifically TG ≥150 mg/dL and HDL-C <40 mg/ dL. 4, 16 Although confirmation of these results is needed in western populations, the reduction of CV events with EPA therapy in a patient population with relatively normal TG levels suggests that EPA may have pleiotropic effects beyond plasma-lipid modification.
It is worth noting that the promising results from JELIS occurred with a high-purity EPA preparation dosed at 1.8 g/d in a Japanese population, for whom the baseline EPA levels are higher than in western populations due to greater dietary intake of marine omega- 19. Drug or alcohol abuse within the past 6 months, and inability/unwillingness to abstain from drug abuse and excessive alcohol consumption during the study 20 . Mental/psychological impairment or any other reason to expect patient difficulty in complying with the requirements of the study or understanding the goal and potential risks of participating in the study Abbreviations: AIDS, acquired immunodeficiency syndrome; apoCII, apolipoprotein CII; CK, creatine kinase; CrCl, creatinine clearance; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA 1c , glycated hemoglobin; HF, heart failure; HIV, human immunodeficiency virus; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; NYHA, New York Heart Association; OM-3, omega-3; PCSK9, proprotein convertase subtilisin/kexin type 9; SBP, systolic blood pressure; TG, triglyceride; ULN, upper limit of normal. Table 1 and Table 2 , respectively. Men or women age ≥45 years with established CVD (CV risk stratum 1, Total mortality Change in body weight and waist circumference Abbreviations: apoB, apolipoprotein B; CHF, coronary heart failure; CV, cardiovascular; DM, diabetes mellitus; ECG, electrocardiography; HDL-C, highdensity lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; hsTnT, high-sensitivity troponin T; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; non-HDL-C, non-high-density lipoprotein cholesterol; PVD, peripheral vascular disease; RLP-C, remnant lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack; UA, unstable angina; VLDL-C, very low-density lipoprotein cholesterol.
| METHODS

REDUCE-IT (NCT01492361) is
1 The first occurrence of any of these major adverse vascular events during the follow-up period of the study will be included in the incidence.
2 For the secondary and tertiary endpoints that count a single event, the time from randomization to the first occurrence of this type of event will be counted for each patient. For secondary and tertiary endpoints that are composites of ≥2 types of events, the time from randomization to the first occurrence of any of the event types included in the composite will be counted for each patient.
3 The time from randomization to occurrence of the first and all recurrent major CV events defined as CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or UA determined to be caused by myocardial ischemia by invasive/noninvasive testing and requiring emergent hospitalization. 4 Including silent MI; ECG will be performed annually for the detection of silent MI.
5 Composite endpoints include: composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, cardiac arrhythmia requiring hospitalization of ≥24 hours, or cardiac arrest; composite of CV death, nonfatal MI (including silent MI), nonelective coronary revascularizations (defined as emergent or urgent classifications), or UA determined to be caused by myocardial ischemia by invasive/noninvasive testing and requiring emergent hospitalization; composite of CV death, nonfatal MI (including silent MI), nonelective coronary revascularizations (defined as emergent or urgent classifications), UA determined to be caused by myocardial ischemia by invasive/noninvasive testing and requiring emergent hospitalization, nonfatal stroke, or PVD requiring intervention such as angioplasty, bypass surgery, or aneurysm repair; and composite of CV death, nonfatal MI (including silent MI), nonelective coronary revascularizations (defined as emergent or urgent classifications), UA determined to be caused by myocardial ischemia by invasive/noninvasive testing and requiring emergent hospitalization, PVD requiring intervention, or cardiac arrhythmia requiring hospitalization of ≥24 hours.
6 Assessment of the relationship between baseline biomarker values and treatment effects within the primary and key secondary composite endpoints; assessment of the effect of study drug on each marker; and assessment of the relationship between post-baseline biomarker values and treatment effects within the primary and key secondary composite endpoints by including post-baseline biomarker values (for example, at 4 months, or at 1 year) as a covariate. inclusion. Fasting TG levels ≥150 mg/dL and <500 mg/dL were required. A study amendment was made during the early part of the trial, increasing the lower end of the fasting TG level from ≥150 mg/ dL to ≥200 mg/dL, to increase enrollment of patients with more significant TG elevations. LDL-C levels needed to be >40 mg/dL and ≤100 mg/dL, with patients on stable statin therapy (AE ezetimibe) for ≥4 weeks prior to the LDL-C and TG qualifying measurements for randomization.
The primary endpoint is a composite of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of CV death, nonfatal MI, or nonfatal stroke. Several other secondary, tertiary, and exploratory endpoints are being assessed (Table 3) that may be unique to EPA relative to other TG-lowering therapies, such as beneficial changes in coronary plaque characteristics, which may lead to reductions in major CV events. 4, 16, [25] [26] [27] [28] [29] [30] [31] [32] [33] However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4) . Part of the reason may involve differences between the classes of drugs studied, such as fibrates, niacin, and omega-3 fatty acids. Even among omega-3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega-3 administered and the ratio of EPA to DHA. [16] [17] [18] [19] [20] [21] [22] [23] [24] In addition, different TG-lowering therapies may exert differential effects across lipid profiles. For example, fibrates and DHA-containing omega-3 fatty acid mixtures have been shown to increase LDL-C, which in turn might adversely influence trial results. Among outcome studies administering TGlowering agents beyond statin therapy, only the JELIS trial using pure EPA demonstrated a significant reduction in CV events in patients with relatively normal TG levels. 16 The subgroup data ( 4, 16 Finally, any benefits to TG-lowering therapies may be most pronounced among statin-treated patients in the higher range of TG elevation (ie, ≥200 mg/dL), [4] [5] [6] for whom randomized prospectively designed outcome studies have not been previously conducted prior to the REDUCE-IT study.
REDUCE-IT is designed to evaluate whether treating at-risk patients with high-dose EPA will lower the rates of important ischemic events beyond statin therapy. However, this trial alone will not validate whether lowering TG specifically in patients with elevated TG levels will result in lower rates of important ischemic events, because the effects of EPA may be broader than TG reduction alone. Several trials, including REDUCE-IT, are ongoing or planned to determine if different TG-lowering therapies in patients with elevated TG levels lower the rate of important ischemic events. [35] [36] [37] [38] The use of different therapeutic agents across these trials may in 
| CONCLUSION
A major remaining question is how to achieve CV risk reduction beyond the benefits realized from effective management of LDL-C. 
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